scholarly journals EFEITOS DA CINESIOTERAPIA SOBRE A FORÇA DE PREENSÃO PALMAR EM INDIVÍDUOS COM DOENÇAS REUMÁTICAS

2018 ◽  
Vol 7 (1) ◽  
pp. 374-387
Author(s):  
Matheus Santos Gomes Jorge ◽  
Willian Guerra De Lima ◽  
Patrícia Rodigheri Vieira ◽  
Letícia Antoniolli Siiss ◽  
Caroline Zanin ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Handgrip Strength ◽  
The Body ◽  
Systemic Lupus ◽  
Artrite Reumatoide ◽  
Systemic Manifestations ◽  
The Right

Introdução: as doenças reumáticas apresentam manifestações musculoesqueléticas e sistêmicas que podem acometer quaisquer regiões do corpo. No caso das mãos, uma das manifestações é a diminuição da força de preensão palmar destes indivíduos. Objetivo: verificar os efeitos da cinesioterapia sobre a força de preensão palmar em indivíduos com doenças reumáticas. Material e métodos: estudo longitudinal e intervencionista com 24 indivíduos portadores de doenças reumáticas (osteoartrite, artrite reumatoide, fibromialgia, lúpus eritematoso sistêmico, esclerose sistêmica e dermatopolimiosite), com idade média de 50,23 anos. Os indivíduos realizaram 10 sessões de fisioterapia, baseadas em cinesioterapia, com exercícios globais e funcionais, 02 vezes por semana, com duração média de 50 minutos, de março de 2014 a novembro de 2015, na Clínica de Fisioterapia da Universidade de Passo Fundo, Passo Fundo/RS. As avaliações inicial e final envolveram a coleta de dados e a mensuração da força de preensão palmar, por meio da dinamometria manual. Resultados: observou-se que os indivíduos apresentaram melhora da força de preensão palmar, porém os resultados foram estatisticamente significativos apenas para a mão direita dos indivíduos com osteoartrite, para ambas as mãos dos indivíduos com artrite reumatoide e lúpus eritematoso sistêmico e para a força de preensão palmar geral dos indivíduos. Conclusão: o protocolo fisioterapêutico proposto produziu aumento da força de preensão palmar de indivíduos com doenças reumáticas.Palavras-chave: Força da mão. Doenças reumáticas. Fisioterapia. Reabilitação. Exercício. ABSTRACT: Introduction: rheumatic diseases present musculoskeletal and systemic manifestations that can affect any region of the body. In the case of the hands, one of the manifestations is the decrease of the handgrip strength of these individuals. Aim: to verify the effects of kinesiotherapy on handgrip strength in individuals with rheumatic diseases. Material and methods: longitudinal and interventional study with 24 individuals with rheumatic diseases (osteoarthritis, rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, systemic sclerosis and dermatopolymyositis), mean age 50.23 years. The individuals performed 10 sessions of physiotherapy, based on kinesiotherapy, with global and functional exercises, 02 times a week, with an mean duration of 50 minutes, from March 2014 to November 2015, at the Physiotherapy Clinic of Passo Fundo University, Passo Fundo/RS. The initial and final evaluations involved data collection and measurement of handgrip strength using manual dynamometry. Results: it was observed that the individuals presented improvement of the handgrip strength, but the results were statistically significant only for the right hand of individuals with osteoarthritis, for both hands of individuals with rheumatoid arthritis and systemic lupus erythematosus and for the handgrip strength of individuals. Conclusion: the proposed physiotherapeutic protocol produced an increase in the handgrip strength of individuals with rheumatic diseases.Keywords: Hand strength. Rheumatic diseases. Physical therapy specialty. Rehabilitation. Exercise.

scholarly journals Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview

Biomedicines ◽  
2020 ◽  
Vol 8 (9) ◽  
pp. 303
Author(s):  
Sandra Rodríguez ◽  
Andrés Muñoz ◽  
Rosa-Helena Bustos ◽  
Diego Jaimes
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adverse Events ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cell Mediated Immunity ◽  
Systemic Lupus ◽  
Biological Drugs ◽  
Necrosis Factor Alpha ◽  
Post Marketing

Since we have gained an understanding of the immunological pathophysiology of rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus, treatment based on biological drugs has become a fundamental axis. These therapies are oriented towards the regulation of cytokines such as tumour necrosis factor-alpha (TNF-α), interleukin (IL)-6, IL-1, and the modulation of cell-mediated immunity (B cells and T cells) by anti CD20 or anti CTAL-4 agents, and can increase the risk of associated infections or adverse events (AE). In this context, the entry of biotherapeutics represented a challenge for pharmacovigilance, risk management and approval by the main global regulatory agencies regarding biosimilars, where efficacy and safety are based on comparability exercises without being an exact copy in terms of molecular structure. The objective of this review is divided into three fundamental aspects: (i) to illustrate the evolution and focus of pharmacovigilance at the biopharmaceutical level, (ii) to describe the different approved recommendations of biopharmaceuticals (biological and biosimilars) and their use in rheumatic diseases (RDs) such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE) and other less frequent RD like cryopyrin-associated autoinflammatory syndromes (CAPS), and (iii) to identify the main AE reported in the post-marketing phase of RD biopharmaceuticals.

scholarly journals Comparative analysis of the systemic inflammatory response in rheumatic diseases

2012 ◽  
Vol 93 (1) ◽  
pp. 12-17
Author(s):  
D V Ivanov ◽  
L A Sokolova ◽  
E Yu Gusev ◽  
L N Kamkina ◽  
N O Plekhanova
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Ankylosing Spondylitis ◽  
Inflammatory Response ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
C Reactive Protein ◽  
Systemic Lupus ◽  
Reactive Protein ◽  
Reactivity Coefficient

Aim. To compare the course of chronic systemic inflammation during various rheumatic diseases. Methods. Examined were three groups of patients: with ankylosing spondylitis - 25 people (20 males and 5 females), with rheumatoid arthritis - 26 people (11 males and 15 females) and with systemic lupus erythematosus - 49 people (3 males and 46 females). The control group included 50 practically healthy individuals (26 males and 24 females). Analyzed were the following parameters: the content of interleukin-6, -8, -10, C-reactive protein. The integral index of the reactivity coefficient was calculated. Results. The level of the studied cytokines was significantly higher in systemic lupus erythematosus, than in ankylosing spondylitis and rheumatoid arthritis, while the content of C-reactive protein was significantly higher in ankylosing spondylitis and rheumatoid arthritis. The values of the reactivity coefficient were also significantly higher in systemic lupus erythematosus. Conclusion. The presence of systemic inflammation was determined in most patients with systemic lupus erythematosus, while ankylosing spondylitis and rheumatoid arthritis were characterized only by mild manifestations of systemic inflammatory response.

scholarly journals Autoimmune thyroid disease and associated rheumatic disorders

2005 ◽  
Vol 133 (Suppl. 1) ◽  
pp. 55-60 ◽  
Author(s):  
Djunajdar Kerimovic-Morina
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Thyroid Disease ◽  
Autoimmune Thyroid Disease ◽  
Systemic Lupus ◽  
Autoimmune Thyroid ◽  
Antithyroid Antibodies

Musculosceletal manifestations were found in patients with hyperthyroidism as well as hypothyroidism. This article will review the available evidence that autoimmune thyroid disease is associated with: Sj?gren?s sydrome (SS), systemic lupus erythematosus (SLE), systemic sclerosis, rheumatoid arthritis (RA) and spondyloarthropathies. Possible pathogenesis of these manifestations has not been completely established. Sj?gren?s syndrome occurs in about 1/10 of patients with autoimmune thyroid disease; patients with SLE and antithyroid antibodies were significantly older than those pattiens without antibodies. Patients with systemic sclerosis and thyroid disease were significantly younger than those without antibodies. Thyroid disfunction was found three times more often in women with RA than in women with noninflammatory rheumatic diseases, and those with thyroid disease tended to have a shorter duration of arthritis.

scholarly journals Beyond Fat Mass: Exploring the Role of Adipokines in Rheumatic Diseases

2011 ◽  
Vol 11 ◽  
pp. 1932-1947 ◽  
Author(s):  
Morena Scotece ◽  
Javier Conde ◽  
Rodolfo Gómez ◽  
Veronica López ◽  
Francisca Lago ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Adipose Tissue ◽  
Rheumatic Diseases ◽  
White Adipose Tissue ◽  
Immune Cells ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Novel Concept

The cloning of leptin in 1994 by Zhang et al. introduced a novel concept about white adipose tissue (WAT) as a very dynamic organ that releases a plethora of immune and inflammatory mediators, such as adipokines and cytokines, which are involved in multiple diseases. Actually, adipokines exert potent modulatory actions on target tissues involved in rheumatic diseases including cartilage, synovial, bone and immune cells. The goal of this paper is to elucidate the recent findings concerning the involvement of adipokines in rheumatic diseases, such as rheumatoid arthritis (RA), osteoarthritis (OA), and systemic lupus erythematosus (SLE).

scholarly journals AB0427 ANTI-NOR90 AUTOANTIBODIES: FAVORABLE OR UNFAVORABLE PROGNOSIS?

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1241.3-1242
Author(s):  
C. Valero ◽  
J. P. Baldivieso ◽  
I. Llorente ◽  
E. F. Vicente-Rabaneda ◽  
L. Esparcia Pinedo. ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Systemic Sclerosis ◽  
Rna Polymerase ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Clinical Characteristics ◽  
Sjogren's Syndrome ◽  
Organ Involvement ◽  
Systemic Lupus

Background:Anti-NOR 90 autoantibodies (anti-NOR90 Ab) are autoantibodies that target nucleolar transcription factor 1 or hUBF, involved in transcription of RNA polymerase I. These autoantibodies have been detected in 6.1% of patients with Systemic Sclerosis (SSc), but their clinical or prognostic significance has not been clearly defined. Anti-NOR90 Ab have been mostly associated with limited scleroderma with mild organ involvement and can also be found in other rheumatic diseases such as rheumatoid arthritis, systemic lupus erythematosus or Sjogren’s syndrome.Objectives:The aim of this study was to identify the main clinical characteristics of patients with positive anti-NOR90 in our Centre.Methods:This is a retrospective, descriptive, cross-sectional study of all patients with positive anti-NOR90 Ab between January 2013 and December 2020 in a single center. Autoantibodies testing was performed using Euroimmun EUROLINE SSc profile IgG autoAb assay kit. Patient demographics, clinical characteristics, associated diagnoses, laboratory and immunological findings were collected.Results:We identified a total of 26 patients with at least a positive value for anti-NOR90 Ab (Table 1). In most cases anti-NOR90 patients were ANA positive, predominantly with nucleolar pattern and coexisted with other SSc autoantibodies. 12 patients had rheumatic diseases and two had SSc, both with limited cutaneous SSc and absence of organ involvement. 14 patients had no definite diagnosis. Clinical features of anti-NOR90 patients are represented in Figure 1. Five patients presented Raynaud’s phenomenon, two cases with pathological nailfold capillaroscopy and one patient had SSc. There was no patient with skin ulcers, calcinosis, interstitial lung disease or pulmonary hypertension. Four patients had gastroesophageal reflux disease and one patient presented antral vascular ectasia. Six patients developed some neoplasm.Figure 1.Clinical characteristics of anti-NOR90 Ab patients.Conclusion:In our case series anti-NOR90 Ab were associated with multiple rheumatic diseases with heterogeneity of clinical manifestations. We did not observe a further progression to SSc or presence of organ involvement or severe scleroderma, so these autoantibodies could be related with a favorable prognosis. In contrast with previous reports, a striking association with cancer has been detected in our population.Table 1.Demographic characteristics and main diagnoses of anti-NOR90 positive patients.CharacteristicsTotal Anti-NOR90: 26 patientsSex, n19 women/ 7 menAge, mean (years)58,9 IQR [46,3-72,2]Race, nAsian: 1; Hispanic: 7; Caucasian: 18Smoker, n3Positive ANA (>1/160), nPattern, n247 Homogeneous, 4 Nucleolar, 4 Speckled, 1 Centromere, 5 Speckled -nucleolar, 3 Homogeneous-nucleolar.Positive ENA, n32 Anti-SSA-Ro52 and Ro60, 1 anti-RNP and anti-SmSystemic sclerosisautoantibodies, n•Anti-Ku: 7•Anti-U3RNP (Fibrilarin): 6•Anti-RNA polymerase III: 5•Anti Th/To: 4•Anti-centromere: 4 (CENP B +/- CENPA)•Anti-topoisomerase I: 2•Anti-Ro52: 3•Anti-PM-Scl: 3Main diagnosis, n12 Rheumatic diseases:2 systemic Sclerosis (2 limited/0 diffuse)1 rheumatoid arthritis1 LES1 Sjögren’s syndrome,3 undifferentiated conective tissue disease2 overlap (1 Sjögren + LES, 1 Sjögren + MCTD 1)s: 1 morphea, 1 cutaneous graft versus host diseaseNeoplasm, n6: 2 solid organ cancer (bladder, kidney), 1 lung adenocarcinoma, 1multiple myeloma, 1 acute myeloid leukemia: 1 basal cell carcinoma.Abbreviations: LES: systemic lupus erythematosus; MCTD: mixed connective tissue diseaseDisclosure of Interests:None declared

Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases

1993 ◽  
Vol 13 (1) ◽  
pp. 58-67 ◽  
Author(s):  
Mansour Al-Janadi ◽  
Suliman Al-Balla ◽  
Abdullah Al-Dalaan ◽  
Syed Raziuddin
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Rheumatic Diseases ◽  
Lupus Erythematosus ◽  
Cytokine Profile ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document